Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0000315066-15-003310.pdf
0000315066-15-003310.rtf
0000315066-15-003310.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000315066-15-003309.pdf
0000315066-15-003309.rtf
0000315066-15-003309.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000315066-15-003308.pdf
0000315066-15-003308.rtf
0000315066-15-003308.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001012975-15-000792.pdf
0001012975-15-000792.rtf
0001012975-15-000792.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000315066-15-003307.pdf
0000315066-15-003307.rtf
0000315066-15-003307.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-15-014787.pdf
0001179110-15-014787.rtf
0001179110-15-014787.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-15-002525.pdf
0001558370-15-002525.rtf
0001558370-15-002525.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-15-002529.pdf
0001558370-15-002529.rtf
0001558370-15-002529.xls
EX-101.INS - EX-101.INS
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-15-014505.pdf
0001179110-15-014505.rtf
0001179110-15-014505.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-15-014506.pdf
0001179110-15-014506.rtf
0001179110-15-014506.xls